Literature DB >> 11685567

Organotypical engineering of differentiated composite-skin equivalents of human keratinocytes in a collagen-GAG matrix (INTEGRA Artificial Skin) in a perfusion culture system.

M Kremer1, E Lang, A Berger.   

Abstract

BACKGROUND: The production of autologous composite skin equivalents for the treatment of full-thickness skin defects in burns is time consuming and costly because of laboratory procedures which have to be performed manually. In the present study keratinocytes were seeded into INTEGRA Artificial Skin and placed in a perfusion culture system in order to evaluate the possibility of producing composite grafts in an automated system with the aim of establishing a cost-effective method of industrial production.
METHODS: Composite grafts of INTEGRA and human keratinocytes were raised in perfusion culture and grafted onto athymic mice to evaluate their potential to reconstitute a full-thickness skin substitute in vivo compared to grafts from standard stagnant cultures.
RESULTS: Cultured composites from perfusion cultures showed no significant histological differences compared to those from stagnant cultures; however, a tendency of improved cell growth and a more surface-oriented localization was observed. Cell proliferation and surface-bound differentiation were not impaired by the use of carbonate-independent buffering (HEPES), which is necessary for perfusion culture. The composite grafts from perfusion culture exhibited identical wound adherence and complete healing and histologically represented a multi-layered, keratinizing human epidermis.
CONCLUSION: Engineering of differentiated composite skin equivalents is possible in a perfusion culture system, which offers technical and procedural and possibly even biological advantages compared to standard stagnant culture methods. The development of automated perfusion culture systems for the production of composite grafts in sizes required clinically (scale-up) will be the next step in the cost-effective engineering of large-scale composite skin equivalents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11685567     DOI: 10.1007/s004230100227

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  7 in total

1.  Wound healing on athymic mice with engineered skin substitutes fabricated with keratinocytes harvested from an automated bioreactor.

Authors:  Balaji Kalyanaraman; Steven T Boyce
Journal:  J Surg Res       Date:  2008-04-29       Impact factor: 2.192

2.  Use of gene-modified keratinocytes and fibroblasts to enhance regeneration in a full skin defect.

Authors:  Jörn Andreas Lohmeyer; Fang Liu; Stefan Krüger; Werner Lindenmaier; Frank Siemers; Hans-Günther Machens
Journal:  Langenbecks Arch Surg       Date:  2011-03-03       Impact factor: 3.445

3.  Bridging the gap between traditional cell cultures and bioreactors applied in regenerative medicine: practical experiences with the MINUSHEET perfusion culture system.

Authors:  Will W Minuth; Lucia Denk
Journal:  Cytotechnology       Date:  2015-04-17       Impact factor: 2.058

4.  Establishing Human Skin Grafts in Mice as Model for Melanoma Progression.

Authors:  Ling Li; Mizuho Fukunaga-Kalabis; Meenhard Herlyn
Journal:  Methods Mol Biol       Date:  2015-12-13

5.  The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression.

Authors:  Ling Li; Mizuho Fukunaga-Kalabis; Meenhard Herlyn
Journal:  J Vis Exp       Date:  2011-08-03       Impact factor: 1.355

6.  A biodegradable magnesium surgical staple for colonic anastomosis: In vitro and in vivo evaluation.

Authors:  Yue Zhang; Jian Cao; Mengmeng Lu; Yi Shao; Kewei Jiang; Xiaodong Yang; Xiaoyu Xiong; Shan Wang; Chenglin Chu; Feng Xue; Yingjiang Ye; Jing Bai
Journal:  Bioact Mater       Date:  2022-10-07

7.  Supportive development of functional tissues for biomedical research using the MINUSHEET® perfusion system.

Authors:  Will W Minuth; Lucia Denk
Journal:  Clin Transl Med       Date:  2012-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.